Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 30;10(9):e30066. doi: 10.1016/j.heliyon.2024.e30066

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors

This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

PMC Copyright notice

Fig. 8 — Immune checkpoints and immunotherapy related to MEX3A in HCC. (A) The distribution of expression of 10 immune checkpoint genes in different tumor stages. (B) Correlation between MEX3A expression and 10 immune checkpoint genes. (C) Correlation between MEX3A expression and TIDE score. (D) Difference of TIDE score between the low- and high-MEX3A expression groups. (E) The comparison of beneficiaries from immunotherapy between the low and high-MEX3A expression groups. (F) Differences of IPS, IPS-CTLA4 blocker, IPS-PD1/PDL1/PDL2 blocker and IPS-CTLA4 and PD1/PDL1/PDL2 blocker between the low and high-MEX3A expression groups. TIDE, Tumor Immune Dysfunction and Exclusion. *P < 0.05; **P < 0.01; ***P < 0.001.